Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05066282 · ClinicalTrials.gov registry record
Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD
A clinical trial, sponsored by Resilient Pharmaceuticals.
- Completed
- Registry status
- 186
- Enrollment target
NCT05066282: Completed study, sponsored by Resilient Pharmaceuticals.
NCT05066282 is a clinical trial that has completed, run by Resilient Pharmaceuticals. The registered enrollment target is 186 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05066282 has completed, sponsored by Resilient Pharmaceuticals.
- COMPLETED
- Registry status
- 186 participants
- Enrollment target
Study Summary
The goal of this long-term follow-up study is to measure how long effects of MDMA-assisted therapy last in participants with PTSD who were treated in a prior Phase 3 clinical trial of MDMA-assisted therapy. The main question it aims to answer is: Does MDMA-assisted therapy result in lasting reductions in PTSD symptoms? Participants who have received at least one dose of MDMA-assisted therapy will take a PTSD assessment at least six months after their last MDMA-assisted therapy session in the main study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2024-05-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05066282
The ClinicalTrials.gov registry entry for NCT05066282 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Resilient Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05066282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05066282 about?
NCT05066282 is a clinical study titled "Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD". The goal of this long-term follow-up study is to measure how long effects of MDMA-assisted therapy last in participants with PTSD who were treated in a prior Phase 3 clinical trial of MDMA-assisted therapy. The main question it aims to answer is: Does MDMA-assisted therapy result in lasting reducti...
What is the current status of trial NCT05066282?
This trial is currently completed. The enrollment target is 186 participants. The study started on 2021-03-01. Estimated completion is 2024-05-21.
Who is sponsoring clinical trial NCT05066282?
This trial is sponsored by Resilient Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.